| Survival |
|
|
|
|
|
|
| Predictive HR: RS≤19 |
1.13 |
0.50 |
2.57 |
LogNormal |
SWOG-8814 |
| Predictive HR: RS>19 |
0.80 |
0.25 |
2.52 |
LogNormal |
SWOG-8814 |
| Prognostic HR: RS≤19 vs. RS>19 |
1.84 |
0.68 |
5.02 |
LogNormal |
SWOG-8814 |
| Time from Progression to Death (RS≤19) (years) |
2 |
1 |
3 |
LogNormal |
[11, 12] |
| Time from Progression to Death (RS>19) (years) |
2 |
1 |
3 |
LogNormal |
[11, 12] |
| Predictive HR: RS≤19 (10 years+) |
1 |
0.75 |
1.25 |
LogNormal |
Assumption |
| Predictive HR: RS>19 (10 years +) |
1 |
0.75 |
1.25 |
LogNormal |
Assumption |
|
| Utilities (Quality of Life) |
|
|
|
|
|
|
| Progression Free, no chemotherapy |
0.8 |
0.7 |
0.9 |
Beta |
[12, 15, 16] |
| Progression Free, chemotherapy |
0.5 |
0.4 |
0.6 |
Beta |
[12, 15, 16] |
| Recurrence |
0.3 |
0.2 |
0.4 |
Beta |
[12, 15, 16] |
|
| Proportion of patients in risk categories and receiving chemotherapy |
|
|
|
|
|
|
| in each risk group: |
|
|
|
|
|
| RS≤19 |
51% |
38% |
64% |
Dirichlet |
SWOG-8814 |
| RS:19-25 |
16% |
12% |
20% |
Dirichlet |
SWOG-8814 |
| RS>25 |
33% |
25% |
41% |
Dirichlet |
SWOG-8814 |
| recieving chemo: |
|
|
|
|
|
| % Receiving Chemotherapy: 21-gene assay Arm, RS≤19 |
45% |
10% |
80% |
Uniform |
[20-23] |
| % Receiving Chemotherapy: 21-gene assay Arrm, RS>19 |
95% |
80% |
100% |
Uniform |
[20-23] |
| % Receiving Chemotherapy: SOC Arm |
95% |
80% |
100% |
Uniform |
[20-23] |
|
| Costs |
|
|
|
|
|
|
| Cost of Adjuvant Chemotherapy |
$28,770 |
$24,492 |
$33,047 |
Normal |
[18] |
| Cost of 21-gene Assay |
$3,800 |
$2,850 |
$4,750 |
Normal |
|
| Cost of Primary Prophylaxis with GCSF |
$15,526 |
$11,645 |
$19,408 |
Normal |
[32] |
| Cost of Secondary Prophylaxis with GCSF |
$5,702 |
$4,277 |
$7,128 |
Normal |
[32] |
| Cost of Recurrence |
$51,137 |
$38,353 |
$63,921 |
Normal |
[11] |
